With no public market to provide competition, the theory among biotech's optimists was that Big Pharma would step in and buy lots of bargains. But cheap prices and easy availability haven't increased drug company appetites: They will only buy what they really want. Deal volumes, both for M&A and alliances, are falling, while Big Pharma has learned to put more of the risk back on biotech. What will change this dynamic, putting more bargaining into biotech hands, is the revival of the public market - and there are hints that such a revival may be on the way.

In Vivo briefly describes these recently founded companies: Axikin Pharmaceuticals, Garnet BioTherapeutics, Medimetriks Pharmaceuticals, Nexomics Biosciences, OrthAlign and Promentis Pharmaceuticals.